These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29351916)

  • 1. Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors.
    Asiedu MK; Thomas CF; Dong J; Schulte SC; Khadka P; Sun Z; Kosari F; Jen J; Molina J; Vasmatzis G; Kuang R; Aubry MC; Yang P; Wigle DA
    Clin Cancer Res; 2018 Apr; 24(7):1691-1704. PubMed ID: 29351916
    [No Abstract]   [Full Text] [Related]  

  • 2. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
    Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
    J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
    Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
    Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
    Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
    Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.
    Walch AK; Zitzelsberger HF; Aubele MM; Mattis AE; Bauchinger M; Candidus S; Präuer HW; Werner M; Höfler H
    Am J Pathol; 1998 Oct; 153(4):1089-98. PubMed ID: 9777940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
    Swarts DR; Ramaekers FC; Speel EJ
    Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.
    Walter RF; Werner R; Ting S; Vollbrecht C; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J; Mairinger FD
    Oncotarget; 2015 Sep; 6(28):24690-8. PubMed ID: 26008974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of mixed pulmonary carcinoma and carcinoid: the driver from their mono-clonal origin.
    Graziano P; Parente P; Centra F; Milione M; Centonze G; Volante M; Cavazza A; Urbano D; Di Maggio G; Balsamo T; Di Micco C; Rossi G; Rossi A; Muscarella LA
    Virchows Arch; 2024 Jan; 484(1):37-46. PubMed ID: 37773451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.
    Voortman J; Lee JH; Killian JK; Suuriniemi M; Wang Y; Lucchi M; Smith WI; Meltzer P; Wang Y; Giaccone G
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13040-5. PubMed ID: 20615970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas.
    Gugger M; Burckhardt E; Kappeler A; Hirsiger H; Laissue JA; Mazzucchelli L
    J Pathol; 2002 Apr; 196(4):408-15. PubMed ID: 11920736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in-silico analysis reveals further evidence of an aggressive subset of lung carcinoids sharing molecular features of high-grade neuroendocrine neoplasms.
    Pelosi G; Melocchi V; Dama E; Hofman P; De Luca M; Albini A; Gemelli M; Ricotta R; Papotti M; La Rosa S; Uccella S; Harari S; Sonzogni A; Asiedu MK; Wigle DA; Bianchi F
    Exp Mol Pathol; 2024 Feb; 135():104882. PubMed ID: 38237798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic changes in the spectrum of neuroendocrine lung tumors.
    Onuki N; Wistuba II; Travis WD; Virmani AK; Yashima K; Brambilla E; Hasleton P; Gazdar AF
    Cancer; 1999 Feb; 85(3):600-7. PubMed ID: 10091733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Proteomic Analysis between Small Cell Lung Carcinoma (SCLC) and Pulmonary Carcinoid Tumors Reveals Molecular Signatures for Malignancy in Lung Cancer.
    Fujii K; Miyata Y; Takahashi I; Koizumi H; Saji H; Hoshikawa M; Takagi M; Nishimura T; Nakamura H
    Proteomics Clin Appl; 2018 Nov; 12(6):e1800015. PubMed ID: 29888431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular pathogenesis and management of bronchial carcinoids.
    Cakir M; Grossman A
    Expert Opin Ther Targets; 2011 Apr; 15(4):457-91. PubMed ID: 21275849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
    Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC
    Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.
    Zhou Z; Zhu L; Niu X; Shen S; Zhao Y; Zhang J; Ye J; Han-Zhang H; Liu J; Liu C; Lu S
    Thorac Cancer; 2019 Apr; 10(4):839-847. PubMed ID: 30793508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology.
    Cros J; Théou-Anton N; Gounant V; Nicolle R; Reyes C; Humez S; Hescot S; Thomas de Montpréville V; Guyétant S; Scoazec JY; Guyard A; de Mestier L; Brosseau S; Mordant P; Castier Y; Gentien D; Ruszniewski P; Zalcman G; Couvelard A; Cazes A
    Neuroendocrinology; 2021; 111(1-2):158-169. PubMed ID: 32015233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?
    Sun TY; Hendifar A; Padda SK
    Curr Oncol Rep; 2022 Jul; 24(7):819-824. PubMed ID: 35305210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.